Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTERED: Allopurinol for Left Ventricular Hypertrophy in End-Stage Renal Disease
2013-001436-22Phase 4Completed
- Sponsor
- University of Dundee
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in end-stage kidney disease (ESKD) and left ventricular hypertrophy (LVH) comparing Allopurinol with Placebo (2 arms). Primary endpoint: Serum urate reduction with allopurinol. Started Jun 2013; status: completed.
02
Drugs
allopurinol
03
Conditions
end-stage kidney disease (ESKD)left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on 2013-001436-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001436-22.